Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
Healthy Volunteers
NCT05028725

Novel Strategy for Early Detection of Esophageal Squamous Cell Carcinoma

Led by University of California, San Francisco · Updated on 2025-03-30

289

Participants Needed

2

Research Sites

189 weeks

Total Duration

On this page

Sponsors

U

University of California, San Francisco

Lead Sponsor

N

National Cancer Institute (NCI)

Collaborating Sponsor

AI-Summary

What this Trial Is About

In the current protocol, we propose a study to evaluate a novel, combined esophageal sponge-methylation biomarker strategy for the early detection of esophageal squamous cell carcinoma (ESCC) as well as its precursor, esophageal squamous dysplasia (ESD). This strategy leverages the 'EsophaCap', a swallowable, retrievable sponge, with subsequent evaluation of the sample using a novel molecular biomarker assay. This biomarker assay evaluates methylation levels in select genes, which have been shown to differ significantly between ESCC cases and controls in pilot studies. Detection of methylation markers highly associated with ESCC could help identify patients with concurrent ESCC or at high risk of imminently developing this condition. If successful, this strategy could result in a paradigm shift for esophageal cancer control strategies in Tanzania and other high-incidence ESCC regions.

CONDITIONS

Official Title

Novel Strategy for Early Detection of Esophageal Squamous Cell Carcinoma

Who Can Participate

Age: 18Years +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female 18 years of age or older at screening visit
  • Patients currently receiving clinical care at Muhimbili National Hospital-Upanga or MNH-Mloganzila
  • ESCC cases: confirmed diagnosis by histology or planned endoscopy with biopsy for suspected ESCC based on clinical criteria
  • Non-ESCC participants: scheduled for endoscopy for non-malignant conditions without esophageal cancer symptoms
  • Ability to swallow liquid (Ogilvie's score less than 3)
  • Well enough to participate in a 20-minute interview or have a close relative to do so
  • Willingness to be contacted in person or by phone 7-10 days after EsophaCap sponge administration
  • Native of Tanzania
  • Written informed consent (and assent if applicable) obtained with ability to comply with study requirements
Not Eligible

You will not qualify if you...

  • Known pregnancy during study participation
  • Any condition or abnormality compromising patient safety or data quality as judged by investigator
  • Clinical instability such as low blood pressure or recent cardiovascular event
  • History of upper gastrointestinal bleeding or peptic ulcer disease within past 3 months
  • Known esophageal varices
  • Use of anticoagulation or antiplatelet medications for high-risk conditions
  • Active extra-esophageal malignancy not in remission
  • History of non-malignant esophageal strictures or esophageal stents
  • History of radiation therapy to head, neck, gastrointestinal tract, or thorax
  • Chemotherapy received within last 12 months
  • Major surgery for esophageal cancer
  • Symptoms or history concerning tracheoesophageal fistula
  • Known small bowel obstruction
  • History of bleeding complications during esophageal biopsy
  • History of head and neck malignancy
  • Known bleeding disorder or thrombocytopenia (platelets less than 50,000 per microliter)
  • Not a permanent resident or native of Tanzania
  • Inability to follow instructions or provide informed consent
  • Allergy to iodine (non-ESCC group)
  • Presence of goiter (non-ESCC group)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Muhimbili National Hospital (MNH)

Dar es Salaam, Mloganzila, Tanzania

Actively Recruiting

2

Muhimbili National Hospital (MNH)

Dar es Salaam, Upganda, Tanzania

Actively Recruiting

Loading map...

Research Team

G

Geoffrey Buckle, MD, MPH

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

DIAGNOSTIC

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Novel Strategy for Early Detection of Esophageal Squamous Cell Carcinoma | DecenTrialz